Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En åpen merknad-forlengelsesstudie av ORKA-001 hos deltakere med plakkpsoriasis

21. oktober 2026 oppdatert av: Oruka Therapeutics, Inc.

En åpen merkeviddeforlengelsesstudie for å evaluere langsiktig sikkerhet, tolerabilitet og effekt av ORKA-001 hos deltakere med moderat til alvorlig plakkpsoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

Studietype

Intervensjonell

Registrering (Antatt)

240

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alberta
      • Edmonton, Alberta, Canada, T5J 3S9
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Edmonton, Alberta, Canada, T6G 1C3
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Surrey, British Columbia, Canada, V3V 0C6
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B IG9
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Ontario
      • Ajax, Ontario, Canada, L1S7K8
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • London, Ontario, Canada, N6H 5L5
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Markham, Ontario, Canada, L3P 1X3
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Peterborough, Ontario, Canada, K9J 5K2
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Toronto, Ontario, Canada, M4W 2N4
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Waterloo, Ontario, Canada, N2J 1C4
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Quebec
      • Montreal, Quebec, Canada, H2X2V1
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Québec, Quebec, Canada, G1V4X7
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Arizona
      • Phoenix, Arizona, Forente stater, 85032
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Arkansas
      • North Little Rock, Arkansas, Forente stater, 72117
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • California
      • Fountain Valley, California, Forente stater, 92708
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90045
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • San Diego, California, Forente stater, 92123
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Santa Ana, California, Forente stater, 92701
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Santa Monica, California, Forente stater, 90403
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Connecticut
      • Cromwell, Connecticut, Forente stater, 06416
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Florida
      • Miami, Florida, Forente stater, 33126
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Illinois
      • Rolling Meadows, Illinois, Forente stater, 60008
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Indiana
      • Plainfield, Indiana, Forente stater, 46168
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Kentucky
      • Bowling Green, Kentucky, Forente stater, 42104
    • Maryland
      • Rockville, Maryland, Forente stater, 20850
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10023
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Mason, Ohio, Forente stater, 45040
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97201
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Portland, Oregon, Forente stater, 97210
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Texas
      • Frisco, Texas, Forente stater, 75033
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77004
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
      • Webster, Texas, Forente stater, 77598
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:
    • Virginia
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed informed consent by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ORKA-001 Once Yearly (High Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentell: ORKA-001 Once Yearly (Low Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentell: ORKA-001 Twice Yearly

Participants will receive ORKA-001 every 6 months per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Ingen inngripen: No Drug

Participants will receive no drug until protocol defined PASI response criterion is met.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 144

Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Day 1 through Week 144

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Time Frame: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time Frame: Day 1 through Week 96
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tidsramme: Day 1 through Week 96

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
PASI Score Over Time
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
IGA Score Over Time
Tidsramme: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. februar 2026

Primær fullføring (Antatt)

1. mai 2030

Studiet fullført (Antatt)

1. juli 2030

Datoer for studieregistrering

Først innsendt

26. februar 2026

Først innsendt som oppfylte QC-kriteriene

26. februar 2026

Først lagt ut (Faktiske)

4. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. oktober 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ORKA-001-113

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .